Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS
- Conditions
- Acquired Immunodeficiency Syndrome
- Interventions
- Biological: Saline SolutionBiological: D-GPEiBiological: M-GPE
- Registration Number
- NCT01881581
- Lead Sponsor
- Centers for Disease Control and Prevention, China
- Brief Summary
This is a randomized, double-blind placebo-controlled dose-escalation clinical trial to evaluate the safety and the immunogenicity of DNA and modified vaccinia virus Ankara (MVA) HIV-1 vaccines in subjects receiving stable highly active antiretroviral therapy (HAART) who have an HIV-1 RNA \< 50 copies/mm3 and CD4+ T cells count ≥ 350 cells/mm3.
- Detailed Description
HIV-infected patients treated with antiretroviral therapy for prolonged periods of time may show decreased levels of HIV-specific immune responses. In these patients, a prime-boost vaccine strategy may induce both humoral and cell-mediated immunity. The hypothesis of this study is that the vaccine strategy selected will be both safe and immunogenic in the patient population being tested.
Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (0.5mg, 2mg or 4mg) intramuscular injections of DNA vaccine (D-GPEi) respectively, the other three groups of patients receive dose-escalation (3×10\^7pfu, 1×10\^8pfu or 3×10\^8pfu) intradermal injections of MVA vaccine (M-GPE), two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. After the maximum tolerated dose of DNA and MVA is identified, DNA prime/ MVA boosting will be tested in another two groups of patients. Lower or the maximum tolerated dose of D-GPEi was used at week 0 and 1, lower or the maximum tolerated dose of M-GPE was used at week 2 and 3, patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 56
- Are willing to participate this study and available for follow-up for the duration of the study.
- Men and women aged 18-50 years.
- Are HIV-positive.
- Have been taking stable anti-HIV drugs for at least 6 months.
- CD4 count ≥ 350 cells/mm3
- Plasma viral load < 50 copies/ml.
- Willing to use acceptable forms of contraception at least 21 days prior to first vaccination until 56 days after the last vaccination.
- Pregnancy or breast-feeding.
- History of previous vaccination with an HIV-1 vaccine.
- Use of immunoinhibitory agents, such as corticosteroids or cytotoxic drugs by oral administration, injection route or inhalation route within 6 months of study entry (But corticosteroids used for allergic rhinitis and skin topical application of corticosteroids were not included); Use of immunomodulatory agents including but not limited to interleukin-2(IL-2） and granulocyte-macrophage colony-stimulating factor (GM-CSF) within 30 days of study entry.
- Use of blood products within 3 months of study entry.
- Use of other experimental drugs within 3 months of study entry.
- Any immunization within 3 months of study entry.
- Comply with any of the following items： Active pulmonary tuberculosis； History of serious adverse reaction to other vaccines； Serious asthma； Have untreated thyroid disease; Syphilis
- Laboratory values（Comply with any of the following items）:
Hemoglobin < 100 g/L (male subjects)，<90 g/L (female subjects)； Absolute neutrophil count ≤ 1000 cells/mm3； Serum creatinine ≥15 mg/L，endogenous creatinine clearance rate <50 ml/min； alanine aminotransferase（ALT）, aspartate aminotransferase(AST) ≥3× upper limit of normal range； Total bilirubin ≥2× upper limit of normal range
- Clinically significant electrocardiogram changes.
- Hypertension ( If it is well controlled by medication and is less than 150/100mmHg , should not be excluded) and other cardiac disease；
- Any medical, psychiatric, social condition, occupational reason judged by the investigator that would limit the evaluation of a subject.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lower dose DNA or Placebo Saline Solution 2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0 Lower dose DNA or Placebo D-GPEi 2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0 Medium dose DNA or Placebo Saline Solution 2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0 Medium dose DNA or Placebo D-GPEi 2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0 High dose DNA or Placebo Saline Solution 2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0 High dose DNA or Placebo D-GPEi 2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0 Lower dose MVA or Placebo Saline Solution 100μL lower dose M-GPE (3×10\^7pfu) or Saline solution at weeks 0 Lower dose MVA or Placebo M-GPE 100μL lower dose M-GPE (3×10\^7pfu) or Saline solution at weeks 0 Medium dose MVA or Placebo Saline Solution 100μL medium dose M-GPE (1×10\^8pfu) or Saline solution at weeks 0 Medium dose MVA or Placebo M-GPE 100μL medium dose M-GPE (1×10\^8pfu) or Saline solution at weeks 0 High dose MVA or Placebo Saline Solution 300μL high dose M-GPE (3×10\^8pfu) or Saline solution at weeks 0 High dose MVA or Placebo M-GPE 300μL high dose M-GPE (3×10\^8pfu) or Saline solution at weeks 0 Low dose DNA+MVA or Placebo control Saline Solution The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3 Low dose DNA+MVA or Placebo control D-GPEi The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3 Low dose DNA+MVA or Placebo control M-GPE The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3 High dose DNA+MVA or Placebo control Saline Solution The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3 High dose DNA+MVA or Placebo control D-GPEi The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3 High dose DNA+MVA or Placebo control M-GPE The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
- Primary Outcome Measures
Name Time Method Occurrence, intensity and relationship to vaccination of local and systemic adverse events 8 months To evaluate the safety and tolerance of a DNA and a replication-defective MVA vaccine expressing HIV-1 gag-pol and env in HIV-1 infected subjects on highly active antiretroviral therapy.
Frequency and severity of adverse events, laboratory abnormalities, and local and systemic reactogenicity signs and symptoms following vaccinations
- Secondary Outcome Measures
Name Time Method Immunogenicity of vaccine 14 months Changes in CD4+ and CD8+ T-cell counts pre- and post-immunization and between the vaccine and placebo groups Changes in viral load pre- and post-immunization and between the vaccine and placebo groups Magnitude and breadth of HIV-1 specific CD8+ T cell responses as determined by interferon-γ(IFN-γ) enzyme-linked immunospot (ELISPOT) using overlapping HIV peptides for gag, pol and env Changes in HIV-1 Gp160-specific antibody responses pre- and post-immunization and between the vaccine and placebo groups
Trial Locations
- Locations (1)
Beijing Ditan Hospital of Capital Medical University
🇨🇳Beijing, China